CurrentNeighborhood Health Plan of Rhode IslandPolicy N/A

Use and coverage of generic oncology drugs

Defines accepted indications, review process, and coverage considerations for generic cancer drugs listed in Attachment A; applies to network providers submitting medication requests to Evolent on behalf of participating health plans.

Policy Summary

PayerNeighborhood Health Plan of Rhode Island

PolicyUse and coverage of generic oncology drugs

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateDec 1, 2025

Next Review DateN/A

Key ActionProvide compendia or peer-reviewed references when requesting off-label use and ensure dosing/monitoring align with CMS-recognized compendia.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

~100+generic oncology drugs listed in Attachment A

Commercial, Exchange, Medicaidapplicable lines of business

Compendia (2025)primary clinical references

Dec 2025implementation

Coverage Criteria

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Core requirements: Drug is listed in Attachment A AND indication, dosing, and monitoring align with CMS-recognized compendia or standard references (e.g., NCCN Drugs & Biologics Compendium, Clinical Pharmacology, Lexi-Drugs, Micromedex, AHFS).

References must be provided for off‑label requests; Evolent follows compendia updates for Attachment A drugs.

Formulary preference: When generic alternatives exist, generic products are preferred over brand‑name products unless there is documented drug shortage, contraindication, confirmed intolerance, or disease progression on the preferred agent.

Continuation requests for previously approved non‑preferred medications are exempt from the preferred agent requirement.

Evidence standard for off‑label use: Off‑label or investigational uses require sufficient supporting evidence as recognized by CMS compendia or acceptable peer‑reviewed literature; isolated case reports or meeting abstracts without full peer‑reviewed articles are insufficient.

ASCO criteria for clinically meaningful outcomes (e.g., HR < 0.80 or OS/PFS benefit ≥ 3 months) may be used to assess clinical meaningfulness.

Requests for a brand-name product when a generic alternative is available are excluded from coverage unless an exception applies. Per policy, generic alternatives are preferred over brand-name drugs for drugs listed in Attachment A; continuation requests for previously approved non-preferred medications are exempt from this preference. An exception to the preference may be allowed when there is a documented drug shortage, disease progression, contraindication, or confirmed intolerance to the preferred agent and the alternative is supported by a compendium or peer-reviewed literature.

Drugs listed in Attachment A are considered not medically necessary when there is disease progression while receiving the same drug or regimen containing the same drug. This exclusion applies when the clinical course demonstrates lack of effectiveness on the ongoing regimen and no other compendium-supported indication justifies continuation of that same agent.

Investigational or off-label uses of generic drugs that lack sufficient evidence as recognized by CMS-recognized compendia or acceptable peer-reviewed literature are considered not medically necessary. The policy defines insufficient evidence to include: patient or regimen characteristics not represented in published studies; outcomes that do not meet clinically meaningful thresholds (for example ASCO benchmarks such as HR < 0.80 or survival benefit >= 3 months); uncontrolled case reports or abstracts without a full peer-reviewed article; or experimental designs that do not adequately address the clinical question. Non-randomized trials with substantial subject numbers may provide supportive evidence, but isolated case reports and abstracts are generally inadequate.

Provider Actions and Review Process

Prior Authorization

Prior Authorization and Clinical Review

Initial Clinical Reviewers will review prior authorization requests to determine if the request meets standards for medical necessity and will issue a determination within the contractual timeframe. If an Initial Clinical Reviewer cannot render a determination, the request will be escalated to a Physician Peer Clinical Reviewer.

All requests reviewed within contractual timeframe
Escalation to Physician Peer Clinical Reviewer as needed

Note

Preferred Medication Guidance

When applicable, generic alternatives are preferred over brand-name drugs. Health plan-specific coverage provisions (including Medicaid or Exchange PDLs) take precedence over this policy per the Preferred Drug Guidelines. Continuation requests for previously approved non-preferred medications are not subject to the preferred-medication requirement. When a documented drug shortage, disease progression, contraindication, or confirmed intolerance to a preferred agent exists, an alternative product may be used if it is medically appropriate and supported by a standard compendium or accepted peer-reviewed literature.

Generic alternatives preferred over brand-name drugs
Health plan PDLs take precedence when they conflict with this policy
Continuation requests for previously approved non-preferred medications are exempt
Allowable alternatives require compendia or peer-reviewed support or documented shortage/intolerance

Denial Risk

Off‑Label / Non‑FDA Labeling Requests

Treatment requests for uses outside the approved FDA manufacturer labeling (off-label requests) must follow CMS Medicare Benefit Policy Manual Chapter 15 and be supported by accepted compendia (e.g., NCCN Drugs and Biologics Compendium, Clinical Pharmacology, Lexi-Drugs, Micromedex, AHFS) or peer-reviewed literature. Lack of supporting compendia or references may result in delays or denial and may render the request non-covered.

Off-label requests must follow CMS Medicare Benefit Policy Manual Chapter 15
Supporting compendia or peer-reviewed literature required (NCCN, Lexi-Drugs, Micromedex, AHFS, Clinical Pharmacology)
Absence of references may delay processing or lead to non-coverage

Denial Risk

Authorization and Reimbursement Risk

Evolent is responsible for processing medication requests from network ordering providers. Medications not authorized by Evolent may be deemed not approvable and therefore not reimbursable.

Medications not authorized by Evolent may be non-reimbursable

Initial Therapy Criteria

Initial therapy

Initial request guidance

Initial requests for drugs listed in Attachment A must align with dosing, indications, and monitoring per CMS‑recognized compendia and standard references (NCCN, Clinical Pharmacology, Lexi‑Drugs, Micromedex, AHFS).

Evolent will follow compendia updates for Attachment A drugs.

Preferred medication guidance: When a generic alternative exists, the generic product is preferred for initial therapy unless plan‑specific PDL or coverage provisions state otherwise.

If a Health Plan Medicaid or Exchange PDL conflicts with this policy, the Health Plan PDL takes precedence per Preferred Drug Guidelines.

Exceptions to preference: An alternative (including a brand‑name product) may be approved for initial therapy when there is documented drug shortage, contraindication, confirmed intolerance, or disease progression on the preferred agent, and the requested product/indication is supported in a standard compendium or peer‑reviewed literature.

For current drug shortages, refer to the FDA drug shortage website.

Continuation Therapy Criteria

Continuation therapy

Continuation requests

Continuation requests for previously approved non‑preferred medications are not subject to the preferred medication guidance and may be authorized consistent with the original approval and supporting compendia references.

Requests for continued therapy must continue to meet compendia‑based dosing/monitoring and will be reviewed for ongoing medical necessity.

Investigational/off‑label continuation: Continuation of investigational or off‑label use that lacked sufficient evidence at initial approval will be evaluated against the same evidentiary standards; insufficient evidence (e.g., case reports, abstracts without full peer‑reviewed articles) may render continued use not medically necessary.

Sufficient evidence considerations include representativeness of patient/cancer characteristics, regimen representation, clinically meaningful outcomes (ASCO criteria), study design appropriateness, and robustness of trial subjects.

Step Therapy and Preferred Alternatives

Preferred generic alternative(s)	Acceptable substitution when preferred agent is not appropriate
When applicable, generic alternatives are preferred over brand-name drugs.	When there is a documented drug shortage, disease progression, contraindication, or confirmed intolerance to a preferred drug/regimen, the available alternative product may be used if deemed medically appropriate and the indication is listed in a standard reference compendium or accepted peer‑reviewed literature.
Continuation requests of previously approved non‑preferred medications are exempt from the preferred agent requirement.	Requests for brand‑name product when a generic alternative is available are excluded (not medically necessary).

Definitions

Generic Drugs — definition

DefinitionA generic drug is identical or bioequivalent to a brand‑name drug in dosage form, safety, strength, route of administration, quality, performance characteristics, and intended use.

FDA approval criteriaContains the same active ingredients as the innovator drug (inactive ingredients may vary); identical in strength, dosage form, and route of administration; has the same use indications; and is bioequivalent.

Manufacturing and quality standardsMust meet the same batch requirements for identity, strength, purity, and quality and be manufactured under FDA Good Manufacturing Practice standards required for innovator products.

Therapeutic equivalence designationsProducts without known or suspected bioequivalence problems are designated AA, AN, AO, AP, or AT; products with resolved bioequivalence issues are designated AB.

Non‑equivalent productsProducts with unresolved or potential bioequivalence problems (often related to specific dosage forms) are designated BC, BD, BE, BN, BP, BR, BS, BT, BX, or B*.

Background

This guideline governs use of generic oncology drugs listed in Attachment A and relies on CMS-recognized compendia and standard references for dosing, indications, and monitoring. Explicitly cited sources include the National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium, Clinical Pharmacology, Lexi-Drugs, Micromedex, and AHFS Drug Information. Off-label or investigational requests must be supported by these compendia or acceptable peer-reviewed literature; lacking such support, uses are treated as investigational or not medically necessary per the policy.